Tissue-directed antibodies and methods of using the same
US-2024342260-A1 · Oct 17, 2024 · US
Compositions and methods for treating obesity
US2016368983A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016368983-A1 |
| Application number | US-201414901799-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 1, 2014 |
| Priority date | Jul 2, 2013 |
| Publication date | Dec 22, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides anti-ghrelin antibodies or antigen-binding molecules that are capable of sequestering ghrelin and inhibiting ghrelin-mediated cellular activities. Also provided in the invention are therapeutic applications of combinations of these antibodies, e.g., to treat or prevent obesity.
First claim
Opening claim text (preview).
What is claimed is: 1 . An antibody comprising heavy and light chains, each having a complementarity determining regions (CDRs) of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175 or each having at least 95% amino acid sequence homology to the CDRs of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175. 2 . The antibody or antigen-binding molecule of claim 1 which is a scFv fragment, an Fv fragment, an Fd fragment, an Fab fragment or an F(ab′) 2 fragment. 3 . An isolated or recombinant polynucleotide which encodes a polypeptide comprising the variable region of the heavy chain or the variable region of the light chain of the antibody of claim 1 . 4 . A hybrid cell line which produces a monoclonal antibody, the monoclonal antibody being specifically reactive with ghrelin and has the specificity of the antibody produced by a hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175. 5 . The cell line of claim 4 , wherein the antibody is a catalytic antibody capable of degrading ghrelin. 6 . The cell line of claim 4 , which has a hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175. 7 . A pharmaceutical composition comprising a therapeutically effective amount of the antibody of claim 1 and a pharmaceutically acceptable vehicle. 8 . The pharmaceutical composition of claim 7 , wherein the antibody is produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175. 9 . The pharmaceutical composition of claim 7 , wherein the antibody is a scFv fragment, an Fv fragment, an Fd fragment, an Fab fragment or an F(ab′) 2 fragment. 10 . A method of reducing weight or slowing weight gain in a subject, comprising administering to the subject a pharmaceutical composition comprising an antibody comprising heavy and light chains, each having a complementarity determining regions (CDRs) of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175 or each having at least 95% amino acid sequence homology to the CDRs of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175, thereby reducing weight or slowing weight gain in the subject. 11 . A method of treating obesity in a subject, comprising administering to the subject a pharmaceutical composition comprising An antibody comprising heavy and light chains, each having a complementarity determining regions (CDRs) of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175 or each having at least 95% amino acid sequence homology to the CDRs of the antibody produced by the hybridoma cell line selected from the group consisting of ATCC™ deposit number PTA-120176, PTA-120174, and PTA-120175, thereby treating obesity in the subject.
Assignees
Inventors
Classifications
F(ab')2 · CPC title
comprising antibodies · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Fab or Fab' · CPC title
Single chain antibody (scFv) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016368983A1 cover?
- The present invention provides anti-ghrelin antibodies or antigen-binding molecules that are capable of sequestering ghrelin and inhibiting ghrelin-mediated cellular activities. Also provided in the invention are therapeutic applications of combinations of these antibodies, e.g., to treat or prevent obesity.
- Who is the assignee on this patent?
- Janda Kim D, Scripps Research Inst
- What technology area does this patent fall under?
- Primary CPC classification C07K16/26. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).